Repository logo
  • Log In
    New user? Click here to register.Have you forgotten your password?
University College Dublin
    Colleges & Schools
    Statistics
    All of DSpace
  • Log In
    New user? Click here to register.Have you forgotten your password?
  1. Home
  2. Institutes and Centres
  3. Systems Biology Ireland
  4. SBI Research Collection
  5. The RASSF8 candidate tumor suppressor inhibits cell growth and regulates the Wnt and NF-κB signaling pathways
 
  • Details
Options

The RASSF8 candidate tumor suppressor inhibits cell growth and regulates the Wnt and NF-κB signaling pathways

Author(s)
Lock, Frances E.  
Underhill-Day, Nicholas  
Dunwel, Thomas  
Matallanas, David  
Kolch, Walter  
et al.  
Uri
http://hdl.handle.net/10197/7761
Date Issued
2010-05-31
Date Available
2016-07-07T14:53:56Z
Abstract
The Ras-assocation domain family (RASSF) of tumor suppressor proteins until recently contained six proteins named RASSF1–6. Recently, four novel family members, RASSF7–10, have been identified by homology searches for RA-domain-containing proteins. These additional RASSF members are divergent and structurally distinct from RASSF1–6, containing an N-terminal RA domain and lacking the Sav/RASSF/Hpo (SARAH) domain. Here, we show that RASSF8 is ubiquitously expressed throughout the murine embryo and in normal human adult tissues. Functionally, RNAi-mediated knockdown of RASSF8 in non-small-cell lung cancer (NSCLC) cell lines, increased anchorage-independent growth in soft agar and enhanced tumor growth in severe combined immunodeficiency (SCID) mice. Furthermore, EdU staining of RASSF8-depleted cells showed growth suppression in a manner dependent on contact inhibition. We show that endogenous RASSF8 is not only found in the nucleus, but is also membrane associated at sites of cell–cell adhesion, co-localizing with the adherens junction (AJ) component β- catenin and binding to E-cadherin. Following RASSF8 depletion in two different lung cancer cell lines using alternative small interfering RNA (siRNA) sequences, we show that AJs are destabilized and Ecadherin is lost from the cell membrane. The AJ components β-catenin and p65 are also lost from sites of cell–cell contact and are relocalized to the nucleus with a concomitant increase in β-catenindependent and nuclear factor-κB (NF-κB)-dependent signaling following RASSF8 depletion. RASSF8 may also be required to maintain actin -cytoskeletal organization since immunofluorescence analysis shows a striking disorganization of the actin- cytoskeleton following RASSF8 depletion. Accordingly, scratch wound healing studies show increased cellular migration in RASSF8-deficient cells. These results implicate RASSF8 as a tumor suppressor gene that is essential for maintaining AJs function in epithelial cells and have a role in epithelial cell migration.
Other Sponsorship
Cancer Research UK
Breast Cancer Campaign
Sport Aiding Medical Research for Kids (SPARKS)
Type of Material
Journal Article
Publisher
Nature Publishing Group
Journal
Oncogene
Volume
29
Issue
30
Start Page
4307
End Page
4316
Copyright (Published Version)
2010 Macmillan Publishers Limited
Subjects

RASSF8

Adherens junctions

Lung cancer

DOI
10.1038/onc.2010.192
Language
English
Status of Item
Peer reviewed
This item is made available under a Creative Commons License
https://creativecommons.org/licenses/by-nc-nd/3.0/ie/
File(s)
Loading...
Thumbnail Image
Name

THE RASSF8 CANDIDATE TUMOUR SUPPRESSOR INHIBITS CELL GROWTH AND REGULATES THE WNT AND NF-ΚB SIGNALLING PATHWAYS VIA ADHERENS JUNCTIONS..pdf

Size

855.84 KB

Format

Adobe PDF

Checksum (MD5)

b3a03e64eb237121eeee6e54795a5743

Owning collection
SBI Research Collection
Mapped collections
Conway Institute Research Collection

Item descriptive metadata is released under a CC-0 (public domain) license: https://creativecommons.org/public-domain/cc0/.
All other content is subject to copyright.

For all queries please contact research.repository@ucd.ie.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Cookie settings
  • Privacy policy
  • End User Agreement